Fundraising Overview - The company, Jiangsu Jicui Yaokang Biotechnology Co., Ltd., has been approved to publicly issue 50 million shares at a price of RMB 10.03979 million, resulting in a net fundraising amount of RMB 1,026.1021 million after deducting issuance costs [1][2] - The funds have been fully received and verified by the accounting firm, with a verification report issued on April 19, 2022 [1] Fund Management and Regulatory Compliance - The company has established a special account for the management of the raised funds and signed a regulatory agreement with the sponsor, Huatai United Securities Co., Ltd., and the bank managing the special account [2][3] - A board meeting and a shareholder meeting were held to approve the allocation of RMB 200 million for a new project focused on "AI-driven organ and animal disease model multimodal preclinical drug research platform" [2][3] Special Account and Agreement Details - The special account has been opened at China Merchants Bank, Nanjing Branch, specifically for the new project [3] - The agreement stipulates that the funds in the special account must only be used for the designated project and outlines the responsibilities of all parties involved, including the sponsor's oversight role [4][5] Oversight and Reporting - The sponsor is required to monitor the use of the funds and conduct semi-annual checks on the account [4][5] - The bank must provide monthly account statements to both the company and the sponsor, ensuring transparency in fund management [5] Agreement Validity and Termination - The agreement will remain in effect until all funds are fully utilized and the account is closed, with provisions for termination in case of non-compliance [6]